GeNO was founded when Dr. David Fine, with a 40 year background in NO and NO2 chemistry, recognized that, given the non-linear kinetics of the reaction of nitric oxide with oxygen, that conventional methodology for delivering inhalable nitric oxide by dilution of concentrated nitric oxide would inevitably lead to the co-delivery of significant amounts of NO2. GeNO’s chemistry minimizes the nitric oxide dilution step and instead starts with dilute NO2, chemically removes one of the oxygen atoms, and generates nitric oxide rapidly and quantitatively.

GeNO has two Investigational New Drug Applications (INDs) using its nitric oxide delivery system. The first clinical study uses NO as a diagnostic agent for administration as an adjunct for right heart catheterization in patients with Pulmonary Arterial Hypertension (WHO Group 1) to add information to improve clinical decision making. The second study is for the treatment of Pulmonary Hypertension in patients with Pulmonary Arterial Hypertension (PAH) and in patients with Pulmonary Hypertension secondary to Idiopathic Pulmonary Fibrosis (PH-IPF). Phase II development programs for both of these indications are ongoing. Detailed information can be found on ClinicalTrials.gov.